Aceclofenac induced Stevens-Johnson/toxic epidermal necrolysis overlap syndrome.

J Pharmacol Pharmacother

Department of General Medicine, Government Stanley Hospital, Chennai, Tamil Nadu, India.

Published: January 2013

The purpose of this paper is to report a rare occurrence of Stevens-Johnson/Toxic epidermal necrolysis (SJS/TEN) overlap syndrome after the use of aceclofenac. A 38 year old healthy adult male presented with rapidly evolving rash over face and upper body with ulceration of buccal mucosa and breathlessness after taking aceclofenac tablet. Naranjo score for this adverse drug event was six, thereby making it a probable adverse drug reaction. Despite aggressive fluid resuscitation and use of antihistamines and systemic steroids, patient's health rapidly worsened and died within six hours of presentation. Aceclofenac induced SJS/TEN overlap is an extremely rare clinical association previously reported only once in medical literature. To the best of our knowledge, this is the first case report of such an association in the Indian population. We are presenting this case to highlight the serious adverse reactions possible from a routinely prescribed drug.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643350PMC
http://dx.doi.org/10.4103/0976-500X.107691DOI Listing

Publication Analysis

Top Keywords

aceclofenac induced
8
stevens-johnson/toxic epidermal
8
epidermal necrolysis
8
overlap syndrome
8
sjs/ten overlap
8
adverse drug
8
aceclofenac
4
induced stevens-johnson/toxic
4
necrolysis overlap
4
syndrome purpose
4

Similar Publications

Strategic development of aceclofenac loaded organosomes for topical application: An explorative ex-vivo and in-vivo investigation for arthritis.

Int J Pharm

December 2024

University Institute of Pharmaceutical Sciences, UGC-centre of Advanced Studies, Panjab University, Chandigarh 160014, India. Electronic address:

Article Synopsis
  • The study focuses on creating aceclofenac-encapsulated organosomes (OS) designed to treat arthritis using a unique combination of phospholipids and organic solvents.
  • The OS formulation showed promising characteristics such as a small size, high drug entrapment efficiency, and improved drug permeability compared to a marketed product, leading to better penetration in skin layers.
  • Results from various arthritis models demonstrated that the OS significantly reduced inflammation markers and was more effective in alleviating arthritis symptoms than the marketed product.
View Article and Find Full Text PDF

Co-Delivery of Aceclofenac and Methotrexate Nanoparticles Presents an Effective Treatment for Rheumatoid Arthritis.

Int J Nanomedicine

March 2024

Biomedical Parasitology and Translational-Immunology Lab, Division of Cell Biology and Immunology, CSIR-Institute of Microbial Technology (IMTECH), Chandigarh, 160036, India.

Background: Rheumatoid arthritis (RA) is a common acute inflammatory autoimmune connective tissue arthropathy. The genetic studies, tissue analyses, experimental animal models, and clinical investigations have confirmed that stromal tissue damage and pathology driven by RA mounts the chronic inflammation and dysregulated immune events.

Methods: We developed methotrexate (MTX)-loaded lipid-polymer hybrid nanoparticles (MTX-LPHNPs) and aceclofenac (ACE)-loaded nanostructured lipid carriers (ACE-NLCs) for the efficient co-delivery of MTX and ACE via intravenous and transdermal routes, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • * A patient experienced severe symptoms—including ulcerations and rashes—after being treated with several drugs, particularly ceftriaxone and aceclofenac + paracetamol, four days post-treatment.
  • * The patient received corticosteroids and other medications after stopping the suspected drugs, highlighting the need for healthcare providers to be vigilant about potential adverse reactions from commonly used medications.
View Article and Find Full Text PDF

Aceclofenac (ACE) is a drug that was precisely devised to circumvent the shortcomings associated with diclofenac. However, ACE too corresponds to nonsteroidal anti-inflammatory drug (NSAID)-related adverse effects, but with a lower amplitude. The present investigation seeks to develop liposomes loaded with ACE adopting a central composite design (CCD) and formulate a chitosan-based hydrogel for synergistic anti-inflammatory efficacy and improved ACE dermal administration.

View Article and Find Full Text PDF

Drug Polymeric Carrier of Aceclofenac Based on Amphiphilic Chitosan Micelles.

ACS Omega

December 2023

Materials Technologies and their Applications Lab, Geology Department, Faculty of Science, Beni-Suef University, Beni-Suef City 62511, Egypt.

Amphiphilic micelles based on chitosan (CS) were applied as drug carriers of aceclofenac (ACF) as a potential method to induce its bioavailability and therapeutic efficiency. -octyl-,-succinyl CS (OSCS), an amphiphilic CS derivative, was successfully synthesized and loaded physically by ACF at different pH values and using different dosages of ACF, forming ACF-loaded polymeric micelles (PMs). The obtained PMs and ACF-loaded PMs were characterized by different analytical techniques, including AFM, TEM, DLS, UV-vis spectrophotometry, H NMR spectroscopy, and FT-IR spectroscopy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!